Cadrenal Therapeutics, Inc. 8-K

What Happened

• On March 12, 2026 Cadrenal Therapeutics, Inc. filed an 8-K (Regulation FD Disclosure and Other Events) and issued a press release (Exhibit 99.1) describing preclinical research on its first‑in‑class 12‑lipoxygenase (12‑LOX) inhibitor, CAD‑1005 (formerly VLX‑1005). The release highlights that 12‑LOX inhibition with CAD‑1005 targets inflammatory consequences of obesity and Type 2 diabetes and builds on prior animal work showing delayed onset of autoimmune diabetes in non‑obese diabetic (NOD) mice.

Key Details

• Filing date: March 12, 2026; press release furnished as Exhibit 99.1.
• Molecule: CAD‑1005, a first‑in‑class 12‑LOX inhibitor (formerly VLX‑1005).
• Preclinical findings reported: oral CAD‑1005 improved glycemic control, reduced pancreatic β‑cell loss, lowered numbers of inflammatory cells in adipose and pancreatic tissues, and decreased pro‑inflammatory cytokines in adipose tissue.
• Company characterizes 12‑LOX inhibition as a selective “switch” that can interrupt chronic inflammation and restore metabolic signaling in obesity/T2D models.

Why It Matters

• For investors, these are preclinical (animal/model) results that highlight a potential therapeutic approach—targeting 12‑LOX—to address inflammation-linked metabolic dysfunction in obesity and Type 2 diabetes.
• The filing does not report clinical trial data or outcomes in humans; it is an update that could shape the company’s R&D narrative and future pipeline milestones, but it is early‑stage evidence rather than proof of clinical efficacy.